Literature DB >> 4555831

Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine.

H Kazamatsuri, C Chien, J O Cole.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4555831     DOI: 10.1001/archpsyc.1972.01750250081011

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


× No keyword cloud information.
  18 in total

1.  Tardive Dyskinesia.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

2.  Tardive dyskinesia: therapeutic options for an increasingly common disorder.

Authors:  Leslie J Cloud; Deepti Zutshi; Stewart A Factor
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 3.  Orofacial dyskinesia. Clinical features, mechanisms and drug therapy.

Authors:  R M Kobayashi
Journal:  West J Med       Date:  1976-10

Review 4.  Assessment of extrapyramidal disorders.

Authors:  C D Marsden; M Schachter
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

Review 5.  Management of tardive dyskinesia: current update.

Authors:  G M Simpson; E H Pi; J J Sramek
Journal:  Drugs       Date:  1982-05       Impact factor: 9.546

6.  Antidyskinetic action of 3-PPP, a selective dopaminergic autoreceptor agonist, in Cebus monkeys with persistent neuroleptic-induced dyskinesias.

Authors:  J E Häggström; L M Gunne; A Carlsson; H Wikström
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575

7.  Pharmacological characterization of tardive dyskinesia.

Authors:  D E Casey; D Denney
Journal:  Psychopharmacology (Berl)       Date:  1977-08-31       Impact factor: 4.530

8.  Effect of baclofen on tardive dyskinesia.

Authors:  J Gerlach; T Rye; P Kristjansen
Journal:  Psychopharmacology (Berl)       Date:  1978-03-01       Impact factor: 4.530

Review 9.  Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Authors:  Nicki Niemann; Joseph Jankovic
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

10.  Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia.

Authors:  C C Huang; R I Wang; A Hasegawa; L Alverno
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.